Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CA-4948 + Zanubrutinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CA-4948 | CA4948|CA 4948|Emavusertib|AU 4948|AU4948|AU-4948 | IRAK4 Inhibitor 8 | CA-4948 inhibits IRAK4, thereby blocking TLR and IL-1R signaling, potentially resulting in tumor regression (PMID: 33335659). | |
| Zanubrutinib | Brukinsa | BGB-3111 | BTK inhibitor 38 | Brukinsa (zanubrutinib) inhibits Bruton tyrosine kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing cells (PMID: 31378456). Brukinsa (zanubrutinib) is FDA approved for use in patients with mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07271667 | Phase II | CA-4948 + Zanubrutinib | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies | Recruiting | USA | 0 |